GlaxoSmithKline PLC (GSK)

GlaxoSmithKline PLC (GSK-N) has received strong endorsements from Stockchase Research Editor Michael O'Reilly, who designates it as a TOP PICK. The company is well-positioned within the healthcare sector, which has demonstrated resilience amid recent market fluctuations. Analysts report an earnings growth of 7%, with GSK trading at an attractive valuation of 11 times earnings and 5.6 times book value, while also boasting a robust 43% return on equity (ROE). The stock's target price is forecasted at $54.31, suggesting an upside potential of approximately 18% from the current levels. Moreover, it provides a healthy dividend yield of 3.3%. O'Reilly encourages investors to implement trailing stops to secure gains as the stock progresses.